The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs

AIDS

Volumn 13, Issue 7, 1999, Pages 797-804

  Murray, Jeffrey S ^a,b   Elashoff, Michael R ^a   Iacono Connors, Lauren C ^a   Cvetkovich, Therese A ^a   Struble, Kimberly A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NONE   (United States)

Author keywords

Antiretroviral therapy; Clinical progression; Clinical trials; Combination therapy; Limit of assay quantification; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DEATH; DEVICE; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; PLASMA; PRIORITY JOURNAL; RISK FACTOR; VIROLOGY; VIRUS LOAD;

ANTI-HIV AGENTS; CLINICAL TRIALS; HIV INFECTIONS; HIV-1; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RNA, VIRAL;

EID: 0032903843     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199905070-00008     Document Type: Article

References (24)

1. 1. Carpenter CC, Fishl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997, 277:1962-1969.
2. 2. Fauci AS, Bartlett JG, Goosby EP, et al.: Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. MMWR 1998, 47(RR-5):43-82.
3. 3. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 355:1142-1143.
4. 4. CAESAR Coordinating Committee: Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: CAESAR trial. Lancet 1997, 349:1413-1421.
5. 5. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
6. 6. Cameron B, Heath-Chiozzi M, Danner S, et al.: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-549.
7. 7. Hammer SM, Katzenstein DA, Hughes MD et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
8. 8. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1017.
9. 9. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331:1173-1180.
10. 10. Sheon AR, Fox HE, Rich KC, et al.: The women and infants transmission study (WITS) of maternal-infant HIV transmission: study design, methods, and baseline data. J Women's Health 1996, 5:69-78.
11. 11. FDA Division of Antiviral Drug Products Advisory Committee Meeting. July 1997, [Transcripts].
12. 12. Dolin R, Amato D Fischl M, et al.: Zidovudine compared to didanosine in patients with advanced HIV-1 infection and little or no previous experience with zidovudine. Arch Intern Med 1995, 155:961-974.
13. 13. D'Aquila RT, Hughes MD, Johnson VA, et al.: Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infections. A randomized, double-blind, controlled trial. Ann Intern Med 1996, 124:1019-1030.
14. 14. Fischl MA, Richman DD, Saag M, et al.: Safety and antiviral activity of combination therapy with zidovudine, zalcitabine and two doses of interferon alpha 2a in patients with HIV. AIDS Clinical Trials Group Study 197. J Acquir Immune Def Syndr Hum Retrovirol 1997, 16:247-253.
15. 3. N Engl J Med 1995, 333:1662-1669.
16. 16. Katlama C, Ingrand D, Loveday C, et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral naïve patients. JAMA 1996, 276:118-125.
17. 17. Bartlett JA, Benoit SL, Johnson VA, et al.: Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. Ann Intern Med 1996, 125:161-172.
18. 18. Staszewski S, Loveday C, Picazo JJ, et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine experienced patients. JAMA 1996, 276:111-117.
19. 19. Montaner JS, Reiss P, Cooper D, et al.: A randomized double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial, Netherlands, Canada and Australia Study. JAMA 1998, 279:930-937.
20. 20. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
21. 21. Drusano GL, Bilello JA, Stein DA, et al.: Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J Infect Dis 1998, 178:360-367.
22. 22. Kempf DJ, Rode RA, Xu Y, et al.: The duration of viral suppression during protease inhibitor therapy for HIV-infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998, 12:F9-F14.
23. 23. Marschner IC, Collieer AC, Coombs RW, et al.: The use of changes in plasma levels of human immunodeficiency virus type 1 RNA levels to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998, 177:40-47.
24. 24. Perelson AS, Essunger P, Cao Y, et al.: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.